A parallel-arm, double-blind, placebo-controlled trial at Mount Sinai's Depression and Anxiety Discovery Center is evaluating a Bioactive Dietary Polyphenol Preparation (BDPP) — comprising Concord grape juice (CGJ), grape seed polyphenol extract (GSPE), and trans-resveratrol (RSV) — across low, medium, and high doses over five weeks in healthy adults aged 18–55. Primary endpoints include pharmacokinetic profiling of absorption and bioavailability, immune function markers, and behavioral stress responses measured via the Trier Social Stress Test (TSST).
This protocol represents an important methodological step rather than a concluded finding — the abstract describes trial design, not results. That distinction matters enormously: the polyphenol-resilience space is littered with promising preclinical data that has repeatedly underperformed in rigorous human trials. Resveratrol's bioavailability challenges are well-documented, and combining it with grape seed proanthocyanidins and CGJ anthocyanins is a pharmacologically thoughtful strategy to leverage synergistic absorption. The TSST is a validated, well-respected acute stress paradigm, lending credibility to the behavioral arm. The 18–55 age range and healthy-volunteer design will limit generalizability to at-risk or older populations where stress resilience interventions are most clinically needed. This is incremental infrastructure-building work — necessary, methodologically sound, but years from actionable clinical guidance. Watch for the results publication, particularly the dose-response pharmacokinetics, which will determine whether any of these three polyphenols achieves physiologically meaningful plasma concentrations.
